Intelligent Bio Net Worth
Intelligent Bio Net Worth Breakdown | INBS |
Intelligent Bio Net Worth Analysis
Intelligent Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Intelligent Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Intelligent Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Intelligent Bio's net worth analysis. One common approach is to calculate Intelligent Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Intelligent Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Intelligent Bio's net worth. This approach calculates the present value of Intelligent Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Intelligent Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Intelligent Bio's net worth. This involves comparing Intelligent Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Intelligent Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Intelligent Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Intelligent Bio's net worth research are outlined below:
| Intelligent Bio is way too risky over 90 days horizon | |
| Intelligent Bio may become a speculative penny stock | |
| Intelligent Bio appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 3.11 M. Net Loss for the year was (10.19 M) with profit before overhead, payroll, taxes, and interest of 1.73 M. | |
| Intelligent Bio Solutions currently holds about 8.28 M in cash with (9.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56. | |
| Intelligent Bio has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum |
Intelligent Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Intelligent Bio Solutions. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intelligent Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of August 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Know Intelligent Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Intelligent Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intelligent Bio Solutions backward and forwards among themselves. Intelligent Bio's institutional investor refers to the entity that pools money to purchase Intelligent Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alyeska Investment Group, L.p. | 2025-03-31 | 613.9 K | Two Sigma Securities, Llc | 2025-03-31 | 0.0 | Altium Capital Management, Lp | 2025-03-31 | 149.3 K | Geode Capital Management, Llc | 2025-03-31 | 49 K | Susquehanna International Group, Llp | 2025-03-31 | 35.5 K | Vanguard Group Inc | 2025-03-31 | 15.5 K | Goldman Sachs Group Inc | 2025-03-31 | 12.8 K | Ubs Group Ag | 2025-03-31 | 1.2 K | Bank Of America Corp | 2025-03-31 | 45.0 | Sbi Securities Co Ltd | 2025-03-31 | 1.0 | Ground Swell Capital, Llc | 2025-03-31 | 0.0 |
Follow Intelligent Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.6 M.Market Cap |
|
Project Intelligent Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.97) | (1.02) | |
| Return On Capital Employed | (1.42) | (1.35) | |
| Return On Assets | (0.66) | (0.70) | |
| Return On Equity | (1.40) | (1.33) |
When accessing Intelligent Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Intelligent Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Intelligent Bio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Intelligent Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Intelligent Bio Solutions. Check Intelligent Bio's Beneish M Score to see the likelihood of Intelligent Bio's management manipulating its earnings.
Evaluate Intelligent Bio's management efficiency
Intelligent Bio Solutions has return on total asset (ROA) of (0.4862) % which means that it has lost $0.4862 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2919) %, meaning that it created substantial loss on money invested by shareholders. Intelligent Bio's management efficiency ratios could be used to measure how well Intelligent Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.02 in 2025. Return On Capital Employed is likely to gain to -1.35 in 2025. At this time, Intelligent Bio's Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 1.3 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 3.3 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.42 | 4.64 | |
| Tangible Book Value Per Share | 2.06 | 2.16 | |
| Enterprise Value Over EBITDA | 0.36 | 0.38 | |
| Price Book Value Ratio | 0.09 | 0.09 | |
| Enterprise Value Multiple | 0.36 | 0.38 | |
| Price Fair Value | 0.09 | 0.09 | |
| Enterprise Value | -5.3 M | -5.1 M |
Intelligent Bio's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Enterprise Value Revenue 3.1673 | Revenue | Quarterly Revenue Growth (0.12) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intelligent Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intelligent Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intelligent Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sakiris Spiro Kevin over six months ago Insider Trading | ||
Sakiris Spiro Kevin over a year ago Disposition of 9394 shares by Sakiris Spiro Kevin of Intelligent Bio subject to Rule 16b-3 | ||
Life Science Biosensor Diagnostics Pty Ltd over a year ago Sale by Life Science Biosensor Diagnostics Pty Ltd of 576028 shares of Intelligent Bio | ||
Towers Christopher over a year ago Purchase by Towers Christopher of 9090 shares of Intelligent Bio | ||
Sakiris Spiro Kevin over a year ago Intelligent Bio exotic insider transaction detected | ||
Sakiris Spiro Kevin over a year ago Intelligent Bio exotic insider transaction detected |
Intelligent Bio Earnings per Share Projection vs Actual
Intelligent Bio Corporate Management
| BBus CA | Chief Officer | Profile | |
| Alex Arzeno | VP Relations | Profile | |
| Victoria Gavrilenko | Operations Manager | Profile | |
| Anna Turkington | Vice Marketing | Profile | |
| Callistus Sequeira | Vice Operations | Profile | |
| Doug Heath | Vice Sales | Profile |
Additional Tools for Intelligent Stock Analysis
When running Intelligent Bio's price analysis, check to measure Intelligent Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intelligent Bio is operating at the current time. Most of Intelligent Bio's value examination focuses on studying past and present price action to predict the probability of Intelligent Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intelligent Bio's price. Additionally, you may evaluate how the addition of Intelligent Bio to your portfolios can decrease your overall portfolio volatility.